<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212455</url>
  </required_header>
  <id_info>
    <org_study_id>2019343H(R2)</org_study_id>
    <nct_id>NCT04212455</nct_id>
  </id_info>
  <brief_title>A Cohort Study on Biomarkers of Hypertension in Guangdong Province(GDP Study)</brief_title>
  <official_title>Establishing Biobank in a Cohort Study for Hypertensive Patients in Guangdong Province(GDP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is the most common chronic diseases and a most important risk factor for
      cardiovascular and cerebrovascular diseases, and also a substantial public health problem.
      The purpose of the study is to investigate the association between biomarkers and adverse
      outcomes in patients with hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population includes subjects who are hypertension, of any race or ethnicity, 18 or
      older years of age, and have provided written informed consent to provide whole blood
      specimens at one or more study visits.

      Physical examination, questionnaire survey and biological sample collection will be conducted
      at baseline and the incidence of all-cause and cardiovascular mortality will be investigated
      during follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2050</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>From date of inclusion until the date of death from any cause, assessed up to 1 year</time_frame>
    <description>All-cause mortality was confirmed through a combination of hospital medical records, telephone contacts with patients or family members, and death registration at the Guangdong Provincial Center for Disease Control and Prevention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>From date of inclusion until the date of death from any cause, assessed up to 1 year</time_frame>
    <description>Cardiovascular mortality was defined as death attributable to an ischemic cardiovascular cause (including fatal MI, stroke).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary outcomes of cardiovascular diseases</measure>
    <time_frame>Through study completion, an average of 1 years</time_frame>
    <description>The number of and the incidence rate of cardiovascular diseases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary outcomes of cerebrovascular diseases</measure>
    <time_frame>Through study completion, an average of 1 years</time_frame>
    <description>The incidence rate of cerebrovascular diseases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary outcomes of kidney</measure>
    <time_frame>Through study completion, an average of 1 years</time_frame>
    <description>The incidence rate of hypertensive renal injure and end-stage renal disease</description>
  </other_outcome>
  <other_outcome>
    <measure>others</measure>
    <time_frame>From date of inclusion until the date of first event, assessed up to 1 year</time_frame>
    <description>Number of participants with reported hospitalization due to other diseases(eg. diabetes， tumor)</description>
  </other_outcome>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional study</intervention_name>
    <description>This is an observational, non-interventional study</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      This study will collect 20 mL whole blood samples from subjects at one or more study visits.
      The whole blood will be processed to plasma and stored for testing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old

          -  In accordance with the diagnosis of hypertension (including Blood pressure ≥140/90mmHg
             and/or taking antihypertensive drugs and/or self-reported hypertension)

        Exclusion Criteria:

          -  &lt;18 years old

          -  Unsigned informed consent

          -  Pregnant Women and Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Ying-qing, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Ying-qing, PhD</last_name>
    <phone>86-2083827812</phone>
    <email>651792209@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HUANG Yu qing, MD</last_name>
    <phone>+8613172054256</phone>
    <email>hyq513@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Ying-qing, PhD</last_name>
      <phone>+862083827812</phone>
      <phone_ext>20984</phone_ext>
      <email>651792209@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Cardiovascular Institute</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FENG Ying-qing, phD</last_name>
      <phone>+862083827812</phone>
      <email>651792209@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Mortality</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

